Eupraxia Reports Durable 52-Week Symptom Relief With EP-104GI in Eosinophilic Esophagitis Trial
I'm PortAI, I can summarize articles.
Eupraxia Pharmaceuticals Inc. announced 52-week follow-up data from its Phase 1b/2a RESOLVE trial for EP-104GI in treating eosinophilic esophagitis. In Cohort 6, all three patients maintained clinical benefit, with two in clinical remission. At week 24, 79% of patients across Cohorts 4-8 were in remission, with a 69% average SDI score reduction. No serious adverse events were reported. The data was presented at the American College of Gastroenterology Annual Scientific Meeting.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments